Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Capsugel opens new quality control laboratory in US
The company’s new global center of excellence houses quality control and testing of raw materials besides specialty testing of finished products for its manufacturing sites and R&D laboratories
The company’s new global center of excellence houses quality control and testing of raw materials besides specialty testing of finished products for its manufacturing sites and R&D laboratories
L19 targets adhesion molecules that anchor blood vessel cells and interferes with the signaling pathway used by cancer cells to stimulate growth of blood vessels. In addition, actinium-225
Tolterodine tartrate tablet of 1mg and 2mg dose strengths is generic equivalent to Pharmacia and Upjohn’s Detrol tablet containing a muscarinic receptor antagonist tolterodine. Tolterodine has a pronounced
Antibodypedia also has the results of approximately 145,000 experiments conducted with the antibodies and 32,000 links to publications related to their use. Antibodypedia co-founder Mathias Uhlén said while
New 190,000ft² facility built to LEED-Gold certified standards, is expected to accommodate 500 employees initially. Biogen Idec chief executive officer George Scangos said the new facility will unite
To make the EMR transition easier, Practice Fusion will also connect with Meridian Health’s laboratories. Meridian Health information technology senior vice president Rebecca Weber said the company is
The new entity will research, develop, manufacture and market new medicines and nutritional products derived from botanical plant origins globally, with focus on gastrointestinal indications and may also
ACG Associated Capsules president and CEO S M J Noronha was quoted by Express Pharma as saying that the construction work of the phase I is almost ready.
The $100m facility, which will be operated by the company’s subsidiary TOT Biopharm, will produce anti-cancer drug injections. In addition, the company’s other new facility producing anti-cancer injections,
Curis president and chief executive officer Dan Passeri said the GDC-0917 agreement adds depth to current pipeline of proprietary targeted anti-cancer agents and further solidifies the company’s relationship